Auswahl der wissenschaftlichen Literatur zum Thema „Gcb-Dlbcl“
Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an
Inhaltsverzeichnis
Machen Sie sich mit den Listen der aktuellen Artikel, Bücher, Dissertationen, Berichten und anderer wissenschaftlichen Quellen zum Thema "Gcb-Dlbcl" bekannt.
Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.
Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.
Zeitschriftenartikel zum Thema "Gcb-Dlbcl"
Pukiat, Sulada, Nuttapong Ngamphaiboon, Pooja Advani, Julio Chavez, George Deeb, Anjana Elefante und Francisco J. Hernandez-Ilizaliturri. „BCL-2 Expression at the Time of Diagnosis Affects the Clinical Outcome of Patients with Germinal Center and Non-Germinal Center Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Chemo-Immunotherpy“. Blood 116, Nr. 21 (19.11.2010): 3130. http://dx.doi.org/10.1182/blood.v116.21.3130.3130.
Der volle Inhalt der QuelleTarius, Jenifer Marsela, Hermawan Istiadi, Ika Pawitra Miranti und Intan Rahmania Eka Dini. „THE CORRELATION BETWEEN CELL OF ORIGIN SUBTYPE WITH OVERALL SURVIVAL OF DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS IN KARIADI GENERAL HOSPITAL SEMARANG“. DIPONEGORO MEDICAL JOURNAL (JURNAL KEDOKTERAN DIPONEGORO) 9, Nr. 3 (12.05.2020): 252–58. http://dx.doi.org/10.14710/dmj.v9i3.27504.
Der volle Inhalt der QuelleGandhi, Shipra, Vishala T. Neppalli, George Deeb, Myron S. Czuczman und Francisco J. Hernandez-Ilizaliturri. „Distinct CD30 Expression Patterns In Germinal Center B-Cell (GCB) and Non-GCB Diffuse Large B-Cell Lymphoma (DLBCL)“. Blood 122, Nr. 21 (15.11.2013): 5064. http://dx.doi.org/10.1182/blood.v122.21.5064.5064.
Der volle Inhalt der QuelleHayama, Miyuki, Masataka Okamoto, Yuki Hagiwara, Ken Tanae, Mika Kohri, Naoki Takahashi, Tadashi Yoshino, Koichi Ohshima und Nozomi Niitsu. „Clinical Significance of Immunohistochemical Markers of Diffuse Large B-Cell Lymphoma In the Rituximab Era.“ Blood 116, Nr. 21 (19.11.2010): 1800. http://dx.doi.org/10.1182/blood.v116.21.1800.1800.
Der volle Inhalt der QuelleKharchenko, Yevgeniya, Tatyana Semiglazova, Anna Artemeva, Galina Kireeva, I. Polyatskin, Ilya Zyuzgin, Larisa Filatova, Yuliya Chudinovskikh, Margarita Motalkina und Yuliya Oleynik. „PROGNOSTIC IMPACT OF IMMUNOHISTOCHEMICAL AND MOLECULAR GENETIC MARKERS IN DIFFUSE LARGE B-CELL LYMPHOMA“. Problems in oncology 66, Nr. 1 (01.01.2020): 79–89. http://dx.doi.org/10.37469/0507-3758-2020-66-1-79-89.
Der volle Inhalt der QuelleAdhi Pangarsa, Eko, Desta Nur Ewika Ardini, Daniel Rizky, Kevin Tandarto, Hermawan Istiadi, Dik Puspasari, Budi Setiawan et al. „The association of Hypoxia-Inducible Factor-2α (HIF-2α) overexpression score with Germinal Center B-Cell Like (GCB) and Non-Germinal Center B-Cell Like (Non-GCB) subtypes of Diffuse Large B-cell Lymphoma (DLBCL)“. Bali Medical Journal 12, Nr. 3 (22.08.2023): 2456–62. http://dx.doi.org/10.15562/bmj.v12i3.4521.
Der volle Inhalt der QuelleMishima, Yuko, Masahiro Yokoyama, Noriko Nishimura, Kyoko Ueda, Tadahiro Gunji, Hideaki Nitta, Yoshiharu Kusano et al. „R-CHOP Therapy Cannot Overcome CD5 Positive Non-GCB Subtype of DLBCL“. Blood 126, Nr. 23 (03.12.2015): 1507. http://dx.doi.org/10.1182/blood.v126.23.1507.1507.
Der volle Inhalt der QuelleChavez, Julio, Mark Walsh, Francisco J. Hernandez-Ilizaliturri, Anjana Elefante und Myron S. Czuczman. „Classification of Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) According to the Han's Criteria Defines Two Groups of Patients with Different Clinical Outcomes Following Systemic Rituximab-Multi Agent Anthracycline-Based Therapy.“ Blood 114, Nr. 22 (20.11.2009): 623. http://dx.doi.org/10.1182/blood.v114.22.623.623.
Der volle Inhalt der QuelleVan Meerten, Tom, Renee Bouwstra, Yuan He, de Boer Janneke, Hilde Kooistra, Rudolf Fehrmann, Emanuele Ammatuna, Gerwin Huls und Edwin Bremer. „CD47 Expression Defines the Efficacy of Rituximab in Non-Germinal Center B-Cell (non-GCB) Diffuse Large B-Cell Lymphoma (DLBCL)“. Blood 132, Supplement 1 (29.11.2018): 2852. http://dx.doi.org/10.1182/blood-2018-99-114561.
Der volle Inhalt der QuelleNiitsu, Nozomi, Naoki Takahashi, Tadashi Yoshino, Masataka Okamoto und Shigeo Nakamura. „Prognostic Significance of EBV Association in Diffuse Large B-Cell Lymphoma in the Rituximab Era“. Blood 126, Nr. 23 (03.12.2015): 3911. http://dx.doi.org/10.1182/blood.v126.23.3911.3911.
Der volle Inhalt der QuelleDissertationen zum Thema "Gcb-Dlbcl"
Prévaud, Léa. „Rôle de la sous-unité c-Rel NFkB dans les Lymphômes B Diffus à Grandes Cellules du Centre Germinatif (GCB-DLBCLs) : établissement d'un modèle murin préclinique“. Electronic Thesis or Diss., Limoges, 2023. http://www.theses.fr/2023LIMO0108.
Der volle Inhalt der QuelleThe transcription factor Rel/NF-kB includes 5 subunits (SU), p50, p52, c-Rel, RelA and RelB which associate into dimers. NF-κB is at the heart of the ontogeny of mature B lymphocytes in the germinal centers (GC) for c-Rel and RelB and during plasma cell differentiation for RelA. Diffuse large cell lymphoma (DLBCL) represent more than 80% of aggressive B-cell lymphomas. We have published that NF-kB SUs must be taken into account differentially, such that RelB is a marker of poor prognosis, RelA is the SU of the ABC molecular subtype (activated B cell) and cRel that of GCB (germinal center B cell)-DLBCL with a novel clean transcriptomic signature. This project consists of understanding mechanistically how c-Rel induces the transformation of a GC B lymphocyte. We have established a new mouse model of c-Rel overexpression (with YFP) in some CG B lymphocytes (tdTomato-AID-Creert2) and are testing the clonal emergence of a tumor. The originality of this inducible model relies in the fact that it makes it possible to follow the competition between the B of the GCs on expressed c-Rel (tdTomato and YFP) compared to their normal counterpart (tdTomato)
Wu, Yen-Fei, und 吳彥霏. „The Role of Galectin-9 in Germinal Centre B-cell-like Diffuse Large B Cell Lymphoma (GCB-DLBCL)“. Thesis, 2016. http://ndltd.ncl.edu.tw/handle/72125881113790583302.
Der volle Inhalt der Quelle國立臺灣大學
免疫學研究所
104
Galectin-9, a tandem-repeat type galectin, was first identified in patients with a nodular sclerosis type of Hodgkin’s disease. Previous studies demonstrated various regulatory roles of galectin-9 in the immune responses. However, role of galectin-9 in cancer biology remains elusive. Here, we found galectin-9 expression in germinal centre B-cell-like diffuse large B cell lymphoma (GCB DLBCLs) was up-regulated amongst germinal center lymphomas. To determine the role of elevated galectin-9 expression in vivo, we used NOD/SCID xenograft model of GCB DLBCLs. Strikingly, we observed a dramatic reduction of tumor volume and weight in mice receiving galectin-9 knockdown GCB DLBCL cells. Interestingly, knockdown of galectin-9 did not affect the tumorigenicity in NOD scid gamma (NSG) xenograft model, which implied natural killer (NK) cells might be responsible for the reduced tumor size in NOD/SCID mice. Thus, depletion of NK cells was achieved by anti-asGM1 antibody in NOD/SCID mice. As a result, we found partially restored tumorigenicity in NOD/SCID mice engrafted with galectin-9 knockdown GCB DLBCLs after NK cell depletion. Moreover, tumor-infiltrating NK cells were significantly increased in galectin-9-depleted tumors in NOD/SCID mice. In term of molecular mechanisms, knockdown of galectin-9 induces neither apoptosis nor cell cycle arrest in GCB DLBCLs. On the other hand, we found that the level of c-Jun, a regulator in tumor microenvironment, was decreased in galectin-9 knockdown GCB DLBCL tumors. These data suggested that galectin-9 derived from GCB-DLBCL might cause the immune escape through inhibiting NK cell activity.
Buchteile zum Thema "Gcb-Dlbcl"
Abraham Jacob, Linu, und Animesh Gupta. „DLBCL Subtypes and Prognosis Based on Immunophenotyping“. In Lymphoma - Recent Advances [Working Title]. IntechOpen, 2023. http://dx.doi.org/10.5772/intechopen.109216.
Der volle Inhalt der QuelleKonferenzberichte zum Thema "Gcb-Dlbcl"
Koning, Marvyn T., Rudolf Übelhart, Arjen H. G. Cleven, Willem H. Zoutman, Sander A. J. van der Zeeuw, Philip Kluin, Marieke Griffioen et al. „Abstract LB-012: Autonomous, antigen-independent B-cell receptor signalling as a novel pathogenetic mechanism in non-GCB DLBCL“. In Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.am2016-lb-012.
Der volle Inhalt der QuelleMaerevoet, Marie, Jason Westin, Catherine Thieblemont, Josee Zijlstra, Brian T. Hill, Fatima De La Cruz Vicente, Sylvain Choquet et al. „Abstract CT132: A Phase 2b randomized study of selinexor in patients with relapsed/refractory Diffuse Large B-Cell Lymphoma (DLBCL) demonstrates durable responses in both GCB & Non-GCB subtypes“. In Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.am2017-ct132.
Der volle Inhalt der QuelleLin, Xiaoyu, Xiaoli Huang, Aparna Sarthy, Terry Magoc, Daniel Albert, Lloyd Lam, Tamar Uziel et al. „Abstract 4706: ABBV-075 exhibits robust in vitro and in vivo activities against the ABC and GCB subtypes of DLBCL“. In Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.am2016-4706.
Der volle Inhalt der QuelleKawagishi, Aki, Hiroki Irie, Yoshio Ogino, Hideya Komatani und Teruhiro Utsugi. „Abstract A274: Novel SYK inhibitors have demonstrated potent antiproliferative effects in both ABC- and GCB-DLBCL cell lines via suppression of multiple pathways downstream of the B-cell receptor.“ In Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics--Oct 19-23, 2013; Boston, MA. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1535-7163.targ-13-a274.
Der volle Inhalt der Quelle